recommended doses of 1 mg/100 lb body weight, or more commonly, at doses of 10 mg/mare. The objective of the present study was to evaluate the effects that single undiluted low doses of the commercially available PGF$_{2\alpha}$ on luteal function and characteristics of the induced estrus and diestrus. We hypothesized that PGF$_{2\alpha}$-induced estrus would be characterized by ovulation rates and luteal function similar to those associated with control estrous cycles.

Eleven horse mares provided 32 estrous cycles that were randomly assigned to the following treatments: T$_1$ ($n = 8$ cycles), 2 mL 0.9% saline solution; T$_2$ ($n = 6$), 10 mg (2 mL) dinoprost tromethamine (DT); T$_3$ ($n = 11$), 2.5 mg (0.5 mL) DT; T$_4$ ($n = 7$), 1.25 mg (0.25 mL) DT. Treatments were administered as single doses intramuscularly during mid-diestrus. Ovolutions and echotexture of the uterus were determined by palpation per rectum and transrectal ultrasonography. Blood samples were taken at intervals between treatment and subsequent induced estrus, and the plasma samples were stored at $-20^\circ$C until assayed for progesterone using RIA techniques. The number of days taken to achieve complete luteolysis (defined as a concentration of plasma progesterone being <1.0 ng/ml) was analyzed by one-way ANOVA on ranks and differences between the control group and PGF$_{2\alpha}$ treatment levels were subsequently compared using the Dunn’s method (SigmaStat for Windows version 2.03, SPSS Inc., Chicago, IL). Same methods were used to analyze the time taken from ovulation until detection of concentrations of plasma progesterone >3 ng/ml, as an indication of luteal function after ovulation.

All treatments with PGF$_{2\alpha}$ successfully induced luteolysis, as evidenced by analyses of concentrations of plasma progesterone; all mares underwent an estrus period following luteolysis. The number of days (mean ± S.E.M.) elapsed from treatment to complete luteolysis (concentration of plasma progesterone <1.0 ng/mL) was 4.7 ± 0.2, 1.6 ± 0.2, 1.8 ± 0.2 and 2.1 ± 0.3 for treatments T$_1$, T$_2$, T$_3$, and T$_4$, respectively ($P < 0.05$). Ovulation was detected in every estrus occurring after treatments. Concentrations of plasma progesterone were ≥3.0 ng/mL in 29 out of 32 cycles 2 days after detection of ovulation and >5.0 ng/mL in all cycles 3–5 days after ovulation ($P > 0.10$).

Recently, a dose as low as 0.5 mg of PGF$_{2\alpha}$ per mare administered as two injections given 24 h apart have been successfully used to induce luteolysis in horse mares [Irvine, et al. Equine Vet J 2002;34:191–4]. In our study, luteolysis was induced with doses as low as 1.25 mg per mare given as a single undiluted injection of Lutalyse$^{\text{Rc}}$. All PGF$_{2\alpha}$-induced estrus in the present study were characterized by normal ovulation and formation of a functional corpus luteum.

**Keywords:** Horse; Prostaglandin; Estrus cycle; Luteal function

**SUPEROVULATION OF MARES: EFFICACY OF A DECREASED eFSH DOSE AND COMPARISON OF OVULATION INDUCING AGENTS**

N.L. Logan, P.M. McCue, M.A. Alonso, E.L. Squires

*Equine Reproduction Laboratory, Colorado State University, Fort Collins, CO 80523, USA*

The use of superovulation in the equine embryo transfer industry is increasing as many breed registries now allow multiple foals to be registered out of the same mare in a single year. The goals of this experiment were to: (1) determine the efficacy of a decreased dose of eFSH in stimulating multiple ovulations and (2) compare the efficacy of hCG and deslorelin in inducing ovulation in eFSH treated mares. Thirty-three normal mares were used for a total of 38 cycles in this study. Mares were examined via transrectal ultrasonography beginning in early April. When a dominant follicle was detected, mares were examined daily to determine the day of ovulation. Once ovulation was confirmed, mares were randomly assigned to one of four treatment groups. Mares in Groups 1 and 2 ($n = 10$ cycles per group) were administered 12.5 mg of eFSH (Bioniche, Inc., Athens, GA) twice daily beginning 5–7 days after ovulation when the majority of follicles were 20–25 mm in diameter. On the second day of treatment, mares were administered 250 µg of cloprostenol intramuscularly. When ≥50% of the cohort of developing follicles was ≥35 mm, eFSH treatment was discontinued, and mares were “coasted” for 36 h and then given either 2500 IU hCG (Group 1) intravenously or 1.5 mg of compounded deslorelin (BET Pharm, LLC, Lexington, KY) intramuscularly (Group 2). Mares in Groups 3 and 4 ($n = 9$ cycles per group) were administered 6.25 mg eFSH twice daily, administered 250 µg of cloprostenol on the second day of treatment, and subsequently given either hCG (Group 3) or deslorelin (Group 4) as described above. All mares were inseminated with one billion progressively motile spermatozoa on the day of hCG or deslorelin administration. A cooled dose of 1 billion progressively motile spermatozoa was inseminated the following day. Mares were subsequently examined daily to detect ovulation. Embryo recovery was attempted 8 days post-ovulation. After the embryo flush, prostaglandins
were administered and mares were randomly re-assigned to a new treatment group. Statistical analysis was performed using one-way analysis of variance (SAS, Cary, NC).

Data are reported as mean ± S.E.M. The number of ovulations for Group 1 mares (5.2 ± 0.8) was greater ($p < 0.05$) than that of all other groups (2.4 ± 0.8, 2.1 ± 0.8, and 2.1 ± 0.8 for mares in Groups 2–4, respectively). Mares treated with deslorelin to induce ovulation were more likely to respond if the number of pre-ovulatory follicles was $\leq 3$ ($p = 0.10$) than if $\geq 4$. Embryo recovery rate per flush was not significantly different between treatment groups. In conclusion, 12.5 mg of eFSH administered twice daily followed by hCG to induce ovulation yielded higher ovulation rates than a lower dose of eFSH and/or administration of deslorelin to induce ovulation.

Keywords: eFSH; Superovulation; Deslorelin; Equine; hCG